Hebel Consulting
The Hebel Consulting Group is a global company providing consulting services for the biopharmaceutical industry supported by offices in the US and Germany.Customer Support
We create a unique process for each client to ensure that business objectives are met and success is achieved.
Our Core Values
Contact Info
- 22 Wingreen Loop, The Hills, TX 78738. USA
- (713)857-4103
- (281)-799-3283
- info@hebelconsulting.com
Blog Archives
By Mark Terry, BioSpace.com Breaking News Staff BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States. Once BioSpace sorted the companies into that group, they were then weighted by a number of […]
Read More
from GenomeWeb NEW YORK (GenomeWeb) – Aiming to simplify and improve the targeted sequencing workflow, LC Sciences is building out its VariantPro multiplexing PCR technology with an eye on a fourth quarter launch. The company is in the midst of testing the technology and recently sent out a call for beta testers to, among other […]
Read More
Today, the Hebel Consulting Group welcomes Prisitine as its newest partner. Pristine develops smart glasses and video collaboration technologies for the life sciences. Wearable technology is changing the way we work. Smart glasses like Google Glass, Vuzix, and others are empowering a new generation of mobile workers to become wearable workers. When time to resolution (TTR) […]
Read More
The problem is that peptides are usually too small and too easily digested by digestive enzymes. We can ‘cut and paste’ genes of interest using a LEGO-like platform technology to produce multi-domain fusion proteins capable of being orally administered. Using powerful bioinformatics search engines, we select compelling candidate genes with the result of a higher […]
Read More
from GenomeWeb NEW YORK (GenomeWeb) – AltheaDx has raised the target amount on its proposed initial public offering to about $74.3 million from $69 million, it disclosed in an amended prospectus filed with the US Securities and Exchange Commission last week. The company said that it expects to fetch between $12 and $14 per share […]
Read More
Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services has announced that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides […]
Read More
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360. Both MEDI4736 and […]
Read More
from Pharma Times by Selina McKee US regulators have asked that Shire include paediatric data in its resubmission of SHP 465 for attention-deficit hyperactivity disorder, throwing yet another obstacle in its bid for approval. SHP 465 (formerly SPD465) has the same active ingredient as the firm’s Adderall XR (mixed amphetamine salts) but is designed to […]
Read More
from Newsworks by Jessica McDonald Without any effective treatments for Ebola, health officials in West Africa are in desperate need of a vaccine to keep the virus from spreading. Stepping into that void, among others, is Inovio Pharmaceuticals of Plymouth Meeting, Pennsylvania. President and CEO of Inovio, Joseph Kim, said beginning early next year their […]
Read More
Parse error: syntax error, unexpected $end in /home/hebelcon/public_html/wp-content/themes/smarton/library/includes/wp-pagenavi.php on line 145